Quick answer
How can semaglutide identity be checked from its formula? The formula on the product page, C187H291N45O59, gives a calculated average mass of about 4113.6 Da and a monoisotopic mass of about 4111.1 Da. In electrospray mass spectrometry a peptide of this size appears as a series of multiply protonated ions, so the observed m/z values are (M + z × 1.00728) ÷ z: about 1372.2 for z = 3, 1029.4 for z = 4, 823.7 for z = 5 and 686.6 for z = 6 on the average-mass scale. This article shows the arithmetic, explains what the structure contributes to the mass, and lists the published degradation work that tells an analyst what unexpected peaks can mean. V8 Peptides supplies a 10 mg lyophilized semaglutide vial, for laboratory research use only.
Most semaglutide structure pages describe the molecule and stop. A laboratory that receives a vial needs something more practical: a way to connect the formula on the label to a number on an instrument. This article does that with formula-only arithmetic, then connects the structure to what is known about its synthesis-related design and its degradation. It does not describe a synthesis procedure. For compound background see the semaglutide research guide and semaglutide brand chemistry. For laboratory research use only.
What the structure contains
The product page describes a 31-amino-acid analog of human GLP-1 with an α-aminoisobutyric acid (Aib) substitution at position 8 and a C18 fatty diacid joined to lysine 26 through a spacer. The discovery paper adds the second amino-acid substitution, Arg at position 34, and explains that the fatty acid moiety and linking chemistry were the key features securing high albumin affinity and receptor potency (reference 1). A structure-activity paper on the preceding liraglutide series found that the spacer region mostly governs potency while the fatty acid governs both potency and protraction, and that fatty-acid length is the most important parameter for protraction (reference 2).
| Structural element | Position | Reported role |
|---|---|---|
| Aib | 8 | Resistance to DPP-4 cleavage (product page) |
| Arg | 34 | Substitution relative to human GLP-1 (reference 1) |
| C18 fatty diacid with spacer | Lys 26 | Albumin binding and prolonged exposure (references 1 and 2) |
| Free N-terminus and C-terminal acid | 1 and 31 | Determine net charge and retention behavior |
These elements matter for analysis because each one changes mass, hydrophobicity or both. The fatty diacid makes the molecule far more retained on reversed-phase columns than native GLP-1 and more prone to adsorb to surfaces.
Calculating mass from the label formula
Take the formula C187H291N45O59. Average mass uses standard atomic weights (C 12.011, H 1.008, N 14.007, O 15.999): M = 187 × 12.011 + 291 × 1.008 + 45 × 14.007 + 59 × 15.999 ≈ 4113.6 Da. Monoisotopic mass uses the most abundant isotope of each element (C 12.0000, H 1.007825, N 14.003074, O 15.994915): M ≈ 4111.1 Da. Which one matters depends on resolution: a low-resolution instrument that cannot resolve isotopes reports a centroid close to the average mass, while a high-resolution instrument resolves the isotopic envelope and the first resolved peak is the monoisotopic value, so a 4 kDa peptide shows an envelope spanning several peaks with the monoisotopic peak not necessarily the tallest.
The calculations above come from the formula and are exact only to the extent that the formula is correct. They are a tool for checking an observed value, not for establishing identity alone.
Expected m/z values by charge state
In positive-mode electrospray, a peptide takes up z protons, and the instrument reports mass-to-charge: m/z = (M + z × 1.00728) ÷ z, where 1.00728 is the proton mass. A peptide with many basic sites (Lys, Arg, His and the N-terminus) can carry several charges, so a series of ions is observed, not a single peak. The table lists the calculated values from the formula; observed values will differ by instrument calibration error.
| Charge z | m/z (average mass) | m/z (monoisotopic) |
|---|---|---|
| 3 | 1372.22 | 1371.38 |
| 4 | 1029.42 | 1028.79 |
| 5 | 823.74 | 823.23 |
| 6 | 686.61 | 686.19 |
| 7 | 588.67 | 588.31 |
To deconvolute, an analyst takes two adjacent peaks in the series, solves for z, and computes M. If the molecular mass obtained does not match the formula within the instrument's stated accuracy, something differs from the label: a different compound, a modification, a salt adduct or an error in the calculation. A sodium adduct adds 21.98 Da to the neutral mass compared with a proton adduct; an oxidation adds 15.995 Da; a deamidation adds 0.984 Da. These shifts are computed from atomic masses and are useful for reading an unfamiliar peak.
Reading the unexpected peaks: what degradation studies show
A 2025 preformulation study used LC-HRMS to follow semaglutide in solution under thermal stress, varying pH, buffer species, molarity and temperature (25 °C and 40 °C). It identified thirteen known impurities and their fragments, reported that six, including products with m/z values such as 2717.21, 4129.64, 3762.28 and 3456.94, were formed under all conditions, and concluded that pH was a key factor in thermal degradation. Some impurities appeared only when water was the solvent (reference 3). The solution-state stress conditions are not those of a refrigerated lyophilized vial, so the paper is best used as a reference for what degradants of this molecule look like, not as a prediction of what a research vial will contain.
General degradation pathways of peptides and proteins (deamidation, isomerization, oxidation, aggregation, hydrolysis) are reviewed in the forced-degradation literature (reference 4), and the chemistry of aspartyl and asparaginyl succinimide reactions has been studied for decades (reference 5). The Aib at position 8 is a non-standard residue to remember when predicting cleavage products; assign peaks by mass first and by hypothesis second.
| Observed shift from parent | Computed value | Possible origin |
|---|---|---|
| +15.995 Da | One oxygen atom | Oxidation |
| +0.984 Da | NH to OH exchange | Deamidation |
| −18.011 Da | Loss of water | Dehydration or cyclization |
| +21.982 Da (vs. H adduct) | Na in place of H | Sodium adduct, not a chemical change |
Synthesis-related impurities, conceptually
Long synthetic peptides can carry process-related impurities as well as degradation products: deletion and insertion sequences, incompletely deprotected species and isomers. Analytical papers stress that quantifying impurities with a UV detector requires attention to relative response factors, since impurities do not necessarily absorb like the parent (reference 6, cited for its title). Immunogenicity assessment of generic peptide impurities is also an active area (reference 7, cited for its title). Neither paper is about semaglutide specifically; they are cited as the analytical backdrop for why an HPLC area percent is a convenient but incomplete measure.
This is the reason a COA usually reports more than one test, and why understanding HPLC purity and HPLC versus mass spectrometry are worth reading together. The V8 page lists purity ≥98% by HPLC and a published lot COA, accessible on the COA page; semaglutide purity testing goes through the fields.
A bench workflow for identity confirmation
- Record the label formula and lot number, and compute the average and monoisotopic masses before the run.
- Prepare a sample from the vial using a fixed diluent, and note concentration (C = m ÷ V; see the reconstitution calculator).
- Acquire a spectrum in positive mode and list the observed m/z series.
- Deconvolute the series to a neutral mass and compare it to the calculated values; report the difference in ppm and Da.
- Examine minor peaks against the shift table; assign adducts before assigning chemistry.
- If a peak is not explained, repeat with a freshly prepared sample to rule out solution-state degradation during preparation.
- File the spectrum, the calculation sheet and the lot record together.
Handling follows the same rules as other lyophilized peptides: refrigerate at 2–8 °C, use −20 °C for long-term holding, and protect from heat, moisture and light, as stated on the product page; see reconstitution and handling and storage and stability.
Where this arithmetic stops
A matching mass confirms composition, not three-dimensional structure or biological activity, and it does not distinguish isomers with identical formulas, such as an Asp-versus-isoAsp change or a different attachment site of the fatty acid. Those require fragmentation data, peptide mapping or orthogonal methods. The cryo-EM structure of semaglutide bound to the GLP-1 receptor and Gs complex is an example of how structure-level information is obtained in a different way, revealing peptide interactions similar to GLP-1 but with different motions within the receptor and the bound peptides (reference 8). In day-to-day laboratory practice, the right claim from a mass check is narrow: "the observed neutral mass agrees with the calculated mass for C187H291N45O59 within the stated error." For sourcing context see where to buy semaglutide; the shop lists the research catalog. All material is for laboratory research use only.
Frequently asked questions
What is the calculated mass of semaglutide from its formula?
From C187H291N45O59, about 4113.6 Da on the average scale and about 4111.1 Da monoisotopic. These are calculated values and depend on the formula being correct.
Why do mass spectra show several peaks?
Electrospray gives multiply protonated ions. Each charge state z has m/z equal to (M + z × 1.00728) ÷ z, so the spectrum is a series that can be deconvoluted to one neutral mass.
What m/z should I expect for the 4+ ion?
About 1029.4 on the average-mass scale and about 1028.8 on the monoisotopic scale, before instrument calibration error.
What do the Aib and the C18 diacid do?
Aib at position 8 resists DPP-4 cleavage. The C18 fatty diacid on lysine 26, with a spacer, drives albumin binding and prolonged exposure according to the discovery and structure-activity papers.
What did the LC-HRMS degradation study find?
Thirteen impurities were identified under solution-state thermal stress, six formed under all conditions, and pH was a key factor. It does not describe a refrigerated lyophilized vial.
How do I tell an adduct from a modification?
Compute the mass shift. A sodium adduct is +21.982 Da relative to a proton adduct; oxidation is +15.995 Da; deamidation is +0.984 Da. Adducts are not chemical changes of the peptide.
Does a matching mass prove the structure?
No. It confirms elemental composition within error but cannot distinguish isomers or confirm folding or activity.
Where are the lot-level data?
On the COA page where a certificate has been published for the lot.
How should the vial be stored?
Refrigerate at 2–8 °C, −20 °C for long-term holding, and protect from heat, moisture and light.
Is this article a synthesis protocol?
No. It uses the label formula for mass arithmetic and summarizes published analytical studies. Semaglutide is supplied for laboratory research use only.
Related reading: Semaglutide GLP-1 Receptor Binding: Assay Design and Math, Semaglutide Half-Life Math: Pharmacokinetics vs Stability, Semaglutide and Insulin: Islet Research Readouts.
References
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80. doi:10.1021/acs.jmedchem.5b00726
- Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thøgersen H, Wilken M, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem. 2007;50(24):6126-32. doi:10.1021/jm070861j
- Malgave A, Akbar S, Joseph A, Dande Aishwarya, Peraman R, Malayandi R. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery. Eur J Pharm Biopharm. 2025;214:114780. doi:10.1016/j.ejpb.2025.114780
- Hawe A, Wiggenhorn M, van de Weert M, Garbe JH, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
- Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J Biol Chem. 1987;262(2):785-94. PMID: 3805008
- Kumar Kuril A. The Critical Need for Implementing RRF in the Accurate Assessment of Impurities in Peptide Therapeutics. Anal Chem. 2025;97(24):12480-12485. doi:10.1021/acs.analchem.5c02149
- De Groot AS, Mattei A, Gabriel B, Calderini J, Roberts BJ, Lelias S, et al. Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches. Pharm Res. 2025;42(5):805-818. doi:10.1007/s11095-025-03843-1
- Zhang X, Belousoff MJ, Liang YL, Danev R, Sexton PM, Wootten D. Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes. Cell Rep. 2021;36(2):109374. doi:10.1016/j.celrep.2021.109374
